Institutional members access full text with Ovid®

Share this article on:

Low-dose eplerenone decreases left ventricular mass in treatment-resistant hypertension

Schneider, Andreasa,b; Schwab, Johannesc,d; Karg, Marina V.b; Kalizki, Tatjanab; Reinold, Annemarieb; Schneider, Markus P.b; Schmieder, Roland E.b; Schmidt, Bernhard M.W.e

doi: 10.1097/HJH.0000000000001264
ORIGINAL PAPERS: Resistant hypertension

Background: Mineralocorticoid receptor antagonists are increasingly used in patients with treatment-resistant hypertension (TRH). There is experimental evidence for blood pressure (BP) independent effects of mineralocorticoid receptor blockade on cardiovascular target organ damage. We hypothesized that low-dose eplerenone (50 mg) will reduce left ventricular mass (LVM) beyond its BP-lowering effects.

Methods: We performed a randomized, double-blind, placebo-controlled, parallel group study in 51 patients with TRH. Patients were allocated to receive either eplerenone 50 mg or placebo for 6 months, while other antihypertensive agents could be added in both groups to achieve a BP target of less than 140/90 mmHg. LVM was assessed by MRI before and after treatment.

Results: Baseline office BP was similar in the eplerenone and the placebo group (166 ± 21/91 ± 15 versus 159 ± 19/94 ± 8 mmHg, n.s.). BP was similarly reduced in the eplerenone versus the placebo group (−35 ± 20/−15 ± 11 versus −30 ± 19/−13 ± 7 mmHg, n.s.). However, LVM was reduced only in the eplerenone group (from 155 ± 33 to 136 ± 33 g, P < 0.001), but not in the placebo group (152 ± 32 versus 148 ± 38 g, P = 0.45).

Conclusions: Despite similar BP-lowering, only patients with TRH who were allocated to eplerenone experienced a reduction of LVM. Thus, our data suggest that in patients with TRH, mineralocorticoid receptor antagonists should be used preferentially in order to achieve an effective reduction of LVM along with the improvement of BP control.

aDepartment of Internal Medicine I, Divisions of Nephrology and Intensive Care, University Hospital Würzburg and Comprehensive Heart Failure Center, Würzburg

bDepartment of Nephrology and Hypertension, Friedrich-Alexander-University, Erlangen-Nürnberg

cInstitute of Radiology and Neuroradiology

dDepartment of Cardiology, Paracelsus Medical University, General Hospital Nürnberg, Nürnberg

eDepartment of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany

Correspondence to Prof. Dr Roland E. Schmieder, MD, Department of Nephrology and Hypertension, Friedrich-Alexander University Erlangen- Nürnberg, Ulmenweg 18, 91054 Erlangen, Germany. Tel: +09131 85 36245; fax: 09131 85 36215; e-mail: Roland.Schmieder@uk-erlangen.de

Abbreviations: ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; ASCOT, Anglo Scandinavian Cardiac Outcomes Trial; ASPIRANT, Addition of spironolactone in patients with resistant arterial hypertension; BP, blood pressure; LVH, left ventricular hypertrophy; LVM, left ventricular mass; RAAS, renin–angiotensin–aldosterone system; TRH, treatment-resistant hypertension

Received 21 September, 2016

Revised 2 December, 2016

Accepted 21 December, 2016

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.